Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIPG-BATS: Molecularly Determined Treatment for DIPG
NCT01182350Phase 2Terminated
- Start
- Sep 2011
- Primary completion
- Jun 2016
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib, temozolomide in diffuse intrinsic pontine glioma (DIPG). Started Sep 2011; status: terminated.
02
Drugs
bevacizumaberlotinibtemozolomide
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT01182350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01182350.